Saturday, October 31, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· November 29, 2025

Marjorie Taylor Greene’s stocks jumped 476% since joining Congress: Here are her 5 biggest investing wins to learn from

View original at finance.yahoo.com
Marjorie Taylor Greene’s stocks jumped 476% since joining Congress: Here are her 5 biggest investing wins to learn from Marjorie Taylor Greene is leaving Congress, but not before one of the best investment runs ever by a sitting politician…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Criticism of her tariff trades is laughable because Trump has talked about tariffs for decades

    80% confidence

  • She learned about Palantir trades from media coverage

    80% confidence

  • Portfolio manager handles all trades under fiduciary agreement

    80% confidence

  • Greene's trades are another reason why stock trading by members of Congress or spouses should be banned

    80% confidence

  • She refuses to hide stock trades in blind trust and reports everything with full transparency

    80% confidence

  • She made all her net worth before becoming Member of Congress

    80% confidence

  • Greene resigned due to bitter falling out with Trump over demands to release Jeffrey Epstein files

    80% confidence

  • Greene is exhibit A for congressional corruption

    80% confidence

  • She doesn't sit on specific subcommittee that oversees ICE

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com